Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Core Insights - Axsome Therapeutics, Inc. reported preliminary net product revenues for the fourth quarter and full year 2025, with total revenues expected to be $196.0 million and $638.5 million, reflecting annual growth rates of 65% and 66% respectively [2][3] Group 1: Financial Performance - AUVELITY is projected to generate net product sales of approximately $155.1 million for the fourth quarter and $507.1 million for the full year 2025 [6] - SUNOSI is expected to achieve net product revenue of around $36.7 million for the fourth quarter and $124.8 million for the full year 2025 [6] - SYMBRAVO is anticipated to have net product sales of about $4.1 million for the fourth quarter and $6.6 million for the full year 2025, following its commercial launch in June 2025 [6] Group 2: Company Overview - Axsome Therapeutics is focused on developing innovative treatments for central nervous system (CNS) disorders, with a portfolio that includes FDA-approved therapies for major depressive disorder, excessive daytime sleepiness, and migraines [4] - The company aims to address significant gaps in care and improve patient outcomes through differentiated products and novel mechanisms of action [4]